Gossamer Bio Inc (GOSS) - Total Liabilities
Based on the latest financial reports, Gossamer Bio Inc (GOSS) has total liabilities worth $291.15 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore GOSS cash flow metrics to assess how effectively this company generates cash.
Gossamer Bio Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Gossamer Bio Inc's total liabilities have evolved over time, based on quarterly financial data. Check GOSS asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Gossamer Bio Inc Competitors by Total Liabilities
The table below lists competitors of Gossamer Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Overseas Commerce Ltd
TA:OVRS
|
Israel | ILA446.32 Million |
|
Nuveen California Select Tax Free Income Closed Fund
NYSE:NXC
|
USA | $795.79K |
|
Alcadon Group AB
ST:ALCA
|
Sweden | Skr737.80 Million |
|
Marisa Lojas S.A
SA:AMAR3
|
Brazil | R$1.83 Billion |
|
SinoMedia Holding Limited
F:SJY
|
Germany | €369.53 Million |
|
The Ruby Mills Limited
NSE:RUBYMILLS
|
India | Rs4.75 Billion |
|
United Bancorp Inc
NASDAQ:UBCP
|
USA | $786.93 Million |
|
MLG OZ Ltd
AU:MLG
|
Australia | AU$174.09 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Gossamer Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GOSS stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gossamer Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gossamer Bio Inc (2016–2024)
The table below shows the annual total liabilities of Gossamer Bio Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $285.80 Million | +14.71% |
| 2023-12-31 | $249.15 Million | -4.31% |
| 2022-12-31 | $260.37 Million | +17.18% |
| 2021-12-31 | $222.19 Million | +1.57% |
| 2020-12-31 | $218.75 Million | +195.13% |
| 2019-12-31 | $74.12 Million | -79.38% |
| 2018-12-31 | $359.49 Million | +4819.78% |
| 2017-12-31 | $7.31 Million | +3892.90% |
| 2016-12-31 | $183.00K | -- |
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical tr… Read more